For: | Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D. Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. World J Diabetes 2021; 12(9): 1426-1441 [PMID: 34630898 DOI: 10.4239/wjd.v12.i9.1426] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v12/i9/1426.htm |
Number | Citing Articles |
1 |
Kayo Masuko. Glucose as a Potential Key to Fuel Inflammation in Rheumatoid Arthritis. Nutrients 2022; 14(11): 2349 doi: 10.3390/nu14112349
|
2 |
Maria Rosa Noliza Encarnacion, Ryota Kawai, Hiroto Kuwabiraki, Nanaka Ban, Hisako Yoshida, Ayumi Shintani, Daisuke Tsuruta, Sho Hiroyasu. Clinical characteristics and outcomes of autoimmune blistering diseases in Japan. The Journal of Dermatology 2025; 52(2): 299 doi: 10.1111/1346-8138.17518
|
3 |
H. Kang, E. B. Lee, S. Lee, T. ‐H. Go, J. Y. Lee, S. ‐H. Lee, S. A. Song, H. K. Lim, S. ‐P. Hong. Dipeptidyl peptidase‐4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance Database. Journal of the European Academy of Dermatology and Venereology 2023; 37(7) doi: 10.1111/jdv.18975
|
4 |
M. Ganeva. SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS. Trakia Journal of Sciences 2023; 21(1): 54 doi: 10.15547/tjs.2023.01.009
|
5 |
Neslihan USLU, Kagan GUNGOR, Gonca TAMER, Bulent CAN. Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases. Medeniyet Medical Journal 2024; : 140 doi: 10.4274/MMJ.galenos.2024.76508
|
6 |
Grigorios Thermos, Nikolaos Katsoulas, George Vilos, Konstantinos I. Tosios. DPP4‐inhibitor‐associated oral mucous membrane pemphigoid. Oral Diseases 2023; 29(5): 2321 doi: 10.1111/odi.14234
|
7 |
Basma Farooq Ali, Ahmed Rahmah Abu-Raghif, Hayder Ridha-Salman, Ali Jihad Hemid Al-Athari. Vildagliptin topical ointment: an effective treatment for imiquimod-induced psoriasis in mice. Journal of Molecular Histology 2025; 56(3) doi: 10.1007/s10735-025-10416-4
|
8 |
Şeyhmus Kaya, Ramazan Oğuz Yüceer, Mustafa Tosun, Reikhan Mustafaeva. The role of C4d expression in the diagnosis of bullous pemphigoid: a clinical and histopathological study. Archives of Dermatological Research 2025; 317(1) doi: 10.1007/s00403-025-04031-2
|
9 |
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.843480
|
10 |
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.830863
|
11 |
Khaled R. Alkharsah, Salma Ali Aljaroodi, Jawad Ur Rahman, Awatif N. Alnafie, Reem Al Dossary, Reem Y. Aljindan, Amani M. Alnimr, Jamal Hussen, Ahmed S. Abdel-Moneim. Low levels of soluble DPP4 among Saudis may have constituted a risk factor for MERS endemicity. PLOS ONE 2022; 17(4): e0266603 doi: 10.1371/journal.pone.0266603
|
12 |
Faten Hadjkacem, Hamdi Frikha, Khouloud Boujelben, Chiraz Chaari, Emna Mnif, Abderrahmen Masmoudi, Tahia Boudawara, Hamida Turki, Mohamed Abid. Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence. Hospital Pharmacy 2023; 58(4): 357 doi: 10.1177/00185787231151861
|